StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report released on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of NASDAQ TTNP opened at $6.13 on Wednesday. Titan Pharmaceuticals has a 12 month low of $4.24 and a 12 month high of $14.80. The business has a 50-day moving average of $5.92 and a 200-day moving average of $6.64.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.